CymaBay’s experienced leadership team brings years of clinical and commercial expertise to advance seladelpar from pipeline to commercialization.
Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Tvardi Therapeutics and the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.
Ms. Dickinson has served as our Chief Regulatory and Quality Assurance Officer since October 2020. Previously, she served as our Chief Regulatory and Compliance Officer since January 2019 and as our Senior Vice President, Regulatory Affairs and Quality Assurance from June 2017 to January 2019. Prior to that she served as Senior Vice President, Chief Regulatory Officer of Anthera. From 2007 to 2014, she was Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. Ms. Dickinson also spent three years at CoTherix, Inc. as Vice President, Regulatory Affairs and Healthcare Compliance Officer, and held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a B.S. in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Dr. Kim joined CymaBay in May 2021 as our Chief Medical Officer. He brings more than 20 years of drug development experience most recently serving as Chief Medical Officer of Afyx Therapeutics, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus. Prior to this, he served in senior leadership roles at Emerald Health Sciences, Zafgen, Orexigen, EnteroMedics and Amylin Pharmaceutical. He received his medical degree from The Chicago School of Medicine, completed his internal medicine residency at Rush University Medical College, and specialty fellowship training in endocrinology/metabolism at University of California, San Diego (UCSD) Medical Center. He also holds a M.B.A. with emphasis in biotechnology structure and strategy from UCSD Rady School of Business.
Dr. McWherter has served as our Chief Scientific officer since 2013. Previously he served as our Senior Vice President, Research and Preclinical Development since July 2007. From 2003 to 2007, he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc. From 2001 to 2003, Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a subsidiary of Pharmacia acquired by Pfizer Inc. in 2003. Dr. McWherter was a Visiting Scientist at the Weizmann Institute of Science in Israel and obtained his Ph.D. in Biophysical Chemistry from Cornell University.
Mr. Stuart joined CymaBay in May 2021 as Chief Commercial Officer. His 25 years of experience crosses marketing, sales, market access and other commercial functions at successful biotech companies and launching new therapies in women’s health, oncology, metabolic, and rare diseases. Mr. Stuart most recently served as Vice President and Prostate Cancer Franchise Leader for Myovant Sciences. In this role he led the company’s Prostate Cancer Launch Readiness cross functional team of commercial, medical, legal, and manufacturing functions. Prior to Myovant, Mr. Stuart held senior leadership roles at several leading biopharmaceutical companies including Genomic Health and CV Therapeutics. He received a B.A. in Communications and Marketing Management from Virginia Polytechnic & State University, with graduate studies at Northeastern University.
Mr. Boehm has served as our Senior Vice President, Human Resources since July 2020 and was previously Vice President, Human Resources since April 2019. Prior to CymaBay, Mr. Boehm served as the Senior Vice President, HR for Aimmune Therapeutics, helping to take them public in 2015. Prior to 2015, he also held SVP or VP Human Resource roles at public and life sciences and high technology companies such as Gilead Sciences, CV Therapeutics, Synopsys, and Palm. Mr. Boehm received a Ph.D.(ABD) from Golden Gate University, his MBA from Pepperdine University, as well as his B.A. in Mathematics from UCLA.
Ms. Filice has served as our Senior Vice President, Portfolio and Product Leadership since November 2020. Prior to CymaBay, she was Senior Vice President, Portfolio and Product Management at Aimmune Therapeutics, where she was a key executive involved in the approval and launch of Palforzia™, an oral immunotherapy indicated for the mitigation of allergic reactions to peanut, and the subsequent merger of the company with Nestle Health Sciences. Prior to Aimmune, Ms. Filice served in senior roles at SFJ Pharmaceuticals and Achaogen. She also spent fifteen years in operational and strategic product development leadership roles at Genentech. Ms. Filice received her Bachelor’s degree in Microbiology from University of California at Davis, and holds an MBA from Santa Clara University.
Dr. Martin has been Senior Vice President, Manufacturing and Nonclinical Development since 2015. Previously, he served as our Vice President of Nonclinical Development and Project Management since 2008. Dr. Martin served as our Sr. Director of Preclinical Development and Project Management from 2006 to 2008 and our Director of Preclinical Development and Project Management from 2004 to 2006. From 1994 to 2004, Dr. Martin served in various positions of increasing responsibility with Roche Palo Alto, a division of F. Hoffman-La Roche Ltd. Dr. Martin obtained his Ph.D. in Biochemistry from the University of California, Davis.
Mr. Menold has served as our Vice President, Finance since April 2017, and was previously Corporate Controller of CymaBay since January 2014. Prior to CymaBay, Mr. Menold served as Corporate Controller for technology firm Zoosk, Inc., and as Controller and Director of Accounting at Affymetrix. Prior to 2005, he also held accounting and finance positions of increasing responsibility at public and private life sciences and high technology companies in the Silicon Valley. Earlier in his career, Mr. Menold was at Ernst & Young where he was an audit manager for life sciences and high technology companies. Mr. Menold received a M.S. in accounting and B.S. in finance from The University of Virginia McIntire School of Commerce.
Mr. O’Mara has served as our Senior Vice President of Business Development since January 2017. Previously, he served as our Vice President of Business Development since August 2006. He joined CymaBay in 1991 and has served CymaBay in a variety of operational and business development positions. Prior to joining CymaBay, Mr. O’Mara held positionsof increasing responsibility at Thymax Corporation and Thomas Research Corp. Mr. O’Mara received a B.A. in Biochemistry from the University of California, Berkeley.
Mr. Quinlan has served as our General Counsel, Chief Compliance Officer and Corporate Secretary since October 2020. He was also our General Counsel and Corporate Secretary from December 2017 to February 2020. Previously, Mr. Quinlan served as General Counsel and Secretary at TerraVia Holdings, Inc. (formerly Solazyme, Inc.) since 2010. From 2005 to 2010, Mr. Quinlan was General Counsel and Secretary at Metabolex, Inc. and from 2000 to 2005, Mr. Quinlan held various positions in the legal department at Maxygen, Inc., most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Mr. Quinlan was an associate at Cooley LLP and Cravath, Swaine & Moore LLP. Mr. Quinlan obtained a law degree from Columbia Law School and a M.Sc. in Medical Biophysics from the University of Toronto.